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5-hydroxymethylcytosine profiling as an indicator 
of cellular state
Epigenetic processes are associated with the reg-
ulation of gene expression through the chemical 
tagging of chromatin and DNA, which can alter 
their interaction with transcription factors [1]. 
Fundamentally, the field of epigenetics is con-
cerned with inherited (but potentially revers-
ible) changes in gene expression or cellular phe-
notype that do not rely on alterations to the 
underlying DNA sequence [1]. This definition 
has been broadened to include nonheritable his-
tone modifications and transient changes asso-
ciated with DNA repair or cell-cycle phases, 
such that modification of DNA, RNA and 
histones is broadly viewed as ‘epigenetic’ in 
character [2]. From this perspective, dynamic 
changes in DNA and histone modifications 
can be observed as embryogenesis proceeds in 
somatic, stem and primordial germ cells, which 
correlate with dynamic changes in gene expres-
sion [3–5]. These epigenetic signatures are char-
acteristic of a particular cell type as they help 
define the associated transcriptome; this is most 
obvious in disease states such as cancer, which 
exhibit altered epigenetic and transcriptomic 
profiles [6–10].
DNA modifications are found to exist at 
cytosine bases in CpG dinucleotide sequences. 
Historically, the most widely studied modifica-
tion of DNA is the incorporation of a methyl 
group onto the fifth carbon of a cytosine base 
to form 5-methylcytosine (5mC) [11]. This heri-
table epigenetic mark has been demonstrated to 
be present in all vertebrates and is proposed to 
be essential for normal development and cellular 
survival. The necessity of 5mC is highlighted 
with the dramatic global loss of 5mC, altered 
gene expression patterns and embryonic lethal-
ity with targeted inactivation of the enzymes 
responsible for the initiation and maintenance 
of normal methylation patterns (the DNA 
methyltransferases [Dnmt1–3]) in mice [12–14]. 
Functionally, promoter 5mC contributes to 
the regulation of transcription at associated 
genes and has also been implicated in genomic 
imprinting, X-chromosome inactivation, tissue-
specific gene regulation and retrotransposon 
silencing [15]. At the same time, potential roles 
for DNA methyltrasferase enzymes indepen-
dent of their catalytic activity should not be 
ignored [16,17].
As originally proposed, DNA methylation 
was generally viewed as a stable epigenetic 
modification [18]. The preference of DNMT1 
for hemimethylated substrates made it ideally 
suited to establish stable differentiated states 
in the absence of genetic mutation [19]. On the 
other hand, large-scale loss and reaccumulation 
of 5mC during murine embryogenesis and cel-
lular differentiation indicated that DNA methy-
lation profiles are ‘reprogrammable’ [4]. The 
identification of the molecular pathways under-
pinning DNA demethylation has a checkered 
history [20]. The recent identification of TET 
proteins as potential regulators of DNA methyl-
ation patterns through the oxidative conversion 
of 5mC to 5-hydroxymethylcytosine (5hmC) 
has sparked intense activity in this research 
area [21]. There has been a growing body of 
inquiry into the function, dysregulation and 
potential significance of 5hmC in physiology 
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and pathology [22,23]. This article will review 
the technologies for 5hmC detection and the 
insights this has given us into 5hmC function. 
This will provide the foundations to discuss 
tissue-specif ic profiles and disease-specif ic 
changes, which may imply that 5hmC is impor-
tant in the pathogenesis of cancer or potentially 
useful as an indicator of disease state.
discovery & technology
5hmC was described in 1952, having been identi-
fied in DNA from bacteriophages and viral DNA 
[24]. It took 20 years before the modification was 
first described in mammals, with the isolation of 
5hmC carried out in rat, mouse and frog brains, 
as well as rat livers, at a yield of approximately 20 
and 6% of cytosine, respectively [25]. However, 
these levels appeared too high and were not repro-
ducible and, as such, were not widely accepted 
[26]. It was after the investigative discovery of 
5hmC in murine neuronal cells in 2009 that the 
interest in this modified base was reignited [27]. 
While aiming to compare quantitative differ-
ences in 5mC between Purkinje and granule cell 
nuclei, Kriaucionis et al. discovered an unusual 
DNA nucleotide using thin layer chromatogra-
phy [27]. They were then able to confirm this to 
be 5hmC with HPLC and mass spectrometry 
[27]. These techniques allowed accurate quantifi-
cation of 5hmC, but it was realized that standard 
techniques to assess 5mC could not differentiate 
the two [28–30].
Digestion of DNA before PCR with methyl-
cytosine-sensitive HpaII and methyl- insensitive 
isoschizomer MspI is able to discriminate 
unmethylated cytosine and 5mC. Differential 
quantification can also be achieved through 
PCR or sequencing after bisulfite conversion of 
cytosine to uracil through deamination, which 
is inhibited by methylation [31–33]. However, 
importantly, 5hmC as well as 5mC was shown 
to completely inhibit HpaII, as well as other 
methyl-sensitive restriction enzymes and 5hmC 
is also resistant to bisulfite deamination [29], thus 
preventing differentiation of 5mC from 5hmC. 
During bisulfite conversion, 5hmC is converted 
to 5-methylenesulfonate, which was shown to be 
less efficiently amplified during PCR, thus rais-
ing the possibility of underestimation of these 
regions [28,34]. These findings highlighted the 
need for reassessment of previous methylation 
data to identify the contribution of 5hmC and 
the need for novel detection methods to allow 
accurate 5hmC localization, quantification and 
assessment of function, particularly as 5mC and 
5hmC may occur in the same DNA fragments.
An overview of 5hmC detection methods 
is shown in Figure 1. 5mC enrichment through 
antibody immunoprecipitation has previously 
been established [35,36]. Initially, 5hmC poly-
clonal and monoclonal antibodies were used for 
semi quantitative purposes, as well as for immu-
noprecipitation and downstream analysis with 
PCR, array profiling or sequencing [37]. Bisulfite 
conversion of 5hmC to 5-methylenesulfonate 
and antibody immunoprecipitation of the con-
verted base has also been demonstrated [34,38]. 
In addition to antibody-mediated methods of 
5hmC enrichment, several groups have since 
developed alternative enrichment strategies. 
Several of these are centered on the selective 
conversion of the modification into a glucosyl-
ated form following incubation with the T4 
β-glucosyltransferase and modified dUTP. 
Following conversion of the 5hmC marks, these 
sugar-coated motifs can be purified by a variety 
of techniques such as selective biotinylation and 
streptavidin pull-down [34,39], or anaylzed fur-
ther through selective methyl sensitive restric-
tion enzyme digests [40,41]. Despite this, none 
of these methods allowed accurate localization 
of 5hmC, which led to the development of 
single-base quantification with oxidative bisul-
fite sequencing (oxBS-seq) and TET-assisted 
bisulfite sequencing (TAB-seq).
oxBS-seq relies on the conversion of 5hmC 
to 5-formylcytosine (5fC) with potassium per-
ruthenate, which does not modify 5mC or cyto-
sine. This 5fC is sensitive to bisulfite conversion 
to uracil. As such, standard bisulfite conversion 
can be performed on untreated DNA, which 
converts only cytosine to uracil, as well as the 
potassium perruthenate-treated DNA, which 
converts both cytosine and 5fC. The two librar-
ies can be subtracted for accurate localization 
and quantification of cytosine, 5mC and 5hmC 
[42]. TAB-seq is performed first by glucosylation 
of 5hmC to prevent oxidation. 5mC is subse-
quently oxidized with excess TET enzymes to 
5-carboxyl cytosine (5caC), without conversion 
of 5hmC. The sample then undergoes standard 
bisulfite conversion, which converts the cytosine 
and 5caC (formerly 5mC) to uracil with pro-
tection of the modified 5hmC. The TAB-seq 
library is then compared with standard bisul-
fite sequence libraries for base-level localization 
and quantification [43]. However, despite these 
advances in single-base resolution profiling 
of 5hmC, these techniques are largely still in 
development and have not been fully embraced 
by the epigenomic community. This is likely 
due to a number of factors: the development 
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of reliable commercial kits for oxBS-seq and 
TAB-seq is still ongoing, particularly as TAB-
seq requires highly active TET enzymes; sec-
ond, many interested groups are still limited 
by the cost of sequencing; oxBS-seq may also 
be limited by the damage and degradation of 
genomic DNA by chemical oxidation condi-
tions and repeated bisulfite treatments required 
for deamination. Nonetheless, these techno-
logical advances underpin our greater aware-
ness of 5hmC distribution and fuel intellectual 
curiosity regarding its potential function and 
interpretation.
Function & distribution
In 2009 Tahiliani and colleagues identified the 
TET enzymes and their role in the methyla-
tion cycle as potential demethylases, based on 
their similarity between mammalian 5mC and 
base J in kinetoplasids (a group of unicellular 
protozoa), which is involved in gene silencing 
[21]. They used a bioinformatics approach to 
identify mammalian homologs of the proteins 
involved in these conversions (JBP1 and JBP2: 
2-oxo glutarate [2OG]- and Fe[II]-dependent 
oxygenases), hypothesizing that if present, 
these would be involved in 5mC modification 
[44]. This led to the discovery of the paralogous 
human proteins TET1, TET2 and TET3 [21], 
which were also demonstrated to be 2OG- and 
Fe(II)-dependent enzymes. Overexpression 
of TET enzymes in human and mouse cells 
resulted in increased 5hmC and decreased 5mC 
detection, with a depletion of TET enzymes 
associated with a reduction of 5hmC [21,45,46]. 
These findings suggested that the TET enzymes 
may cause oxidation of 5mC to 5hmC and led 
to studies investigating the function of 5hmC. 
A number of groups hypothesized that 5hmC 
was an intermediate in a DNA demethylation 
pathway [47,48].
The mechanisms of 5hmC involvement in 
demethylation were proposed to be both active 
and passive. In the passive model, the usual 
mechanism for maintenance of 5mC is dis-
rupted. During cell division, DMNT1 is able 
to recognize hemimethylated DNA in con-
cert with recruitment by UHRF1 [49–51]. This 
results in subsequent methylation of the daugh-
ter strand based on the pattern of the parent 
strand, thus maintaining a symmetrical pattern 
through cell division. However, DMNT1 has 
reduced binding to 5hmC compared with 5mC 
[52,53]. Therefore, the conversion of 5mC to 
5hmC prevents DMNT1 binding to the parent 
strand with resulting loss of methylation on the 
daughter strand. This has been supported by an 
in vivo study revealing passive 5hmC loss in the 
paternal mouse zygote during preimplantation 
[54]. Nonetheless, although the model of pas-
sive demethylation is supported by a number 
of groups, it has not been directly shown that 
the presence of 5hmC in early zygotes equates 
to a loss of 5mC. The exact mechanism is not as 
clear, as the UHRF1 cofactor has been shown to 
bind with equal efficiency to 5mC and 5hmC, 
therefore raising questions over the DMNT1 
maintenance mechanism and the role of 5hmC 
in preventing such a mechanism from working 
[55]. Furthermore, a recent study confirmed that 
while exogenous UHRF1 in embryonic stem 
(ES) cells improves localization of DMNT1, it 
does not affect methylation dynamics [56]. There 
have also been a number of potential active 
pathways proposed for the DNA demethylation 
process (Figure 2).
It has been shown that the TET enzymes 
facilitate the progressive oxidation of 5mC to 
5hmC, and subsequently to the recently iden-
tified 5fC and 5caC derivatives [57–59]. The 
de carboxylation of 5caC has been proposed as 
a candidate route of demethylation, akin to the 
process of demethylation of thymine to uracil 
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Figure 1. Global, locus-specific and single nucleotide resolution of 
5-hydroxymethylation detection methods. HPLC, mass spectrometry , ELISA 
and DNA dot-blot techniques provide global assessment of 5hmC levels. Locus-
specific assessment of 5hmC can be achieved through antibody 
immunoprecipitation of 5hmC directly or CMS following bisulphite conversion of 
5hmC to CMS. Other locus-specific detection methods rely on the glucosylation of 
5hmC with subsequent pull-down techniques, selective labeling with biotin and 
chemical capture or selective methyl-sensitive restriction enzyme digestion 
approaches. Single nucleotide resolution profiling of 5hmC can be achieved 
through two methods, either oxidative bisulfite sequencing or TET-assisted bisulfite 
sequencing. oxBS-seq relies on the oxidative conversion of 5hmC to 
5-formylcytosine by potassium perruthenate, which is susceptible to bisulfite 
conversion such as unmodified cytosine. While during TAB-seq, 5hmC is protected 
from bisulfite conversion and 5mC is made sensitive through glucosylation and 
oxidation to 5hmC and 5-carboxylcytosine, respectively. These unique oxBS-seq 
and TAB-seq libraries can be subtracted from standard bisulfite-sequence libraries 
to give profiling of relative 5hmC and 5mC. 
5hmC: 5-hydroxymethylation; CMS: 5-methylenesulfonate.
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in yeast [60], but no such carboxylase has yet 
been identified in mammals. Alternatively, it 
has been suggested that demethylation occurs 
through deamination of 5hmC to 5-hydroxy-
methyluracil with subsequent base-excision 
repair, resulting in a nonmodified CpG dinu-
cleotide [61–63]. Once more, the evidence sup-
porting such a pathway has also been called 
into question. Despite the finding that the AID 
and APOBEC enzymes can deaminate 5mC 
in vitro, and that they are significantly expressed 
in murine tissue and primordial germ cells in 
which demethylation occurs [64,65], they were 
found to have greater affinity for cytosine bind-
ing than for 5mC or 5hmC. Additionally, over-
expression of AID/APOBEC did not result in 
increased detection of deamination products or 
reduction in 5fC or 5caC [66]. Instead, the most 
likely mode of active demethylation appears to 
be regulated by TDG-mediated base-excision 
repair [57,67–71]. In two recent papers, both 5caC 
and 5fC were mapped across the genome of 
mouse ES cells for the first time, with extremely 
low levels of enrichment observed [70,71]. This is 
likely due to the fact that these modifications 
are not stable, but are instead rapidly turned 
over transient marks of active DNA demeth-
ylation. However, upon the reduction of the 
TDG enzyme by both shRNAi, as well as in 
a knockout model, ectopic regions of 5fC and 
5caC become apparent and were seen over genic 
and promoter-proximal regions, with a particu-
lar enrichment over poised (H3K4me1 but not 
H3K27ac-marked) enhancer elements. Taken 
together with the finding that depletion of the 
TDG enzyme in mouse ES cells leads to accu-
mulation of 5caC to detectable levels, this sug-
gests that this is a likely mechanism for active 
demethylation events [57]. Nevertheless, it is of 
note that the detection of 5fC and 5caC in the 
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Figure 2. Proposed models of TeT-mediated dNA demethylation pathways. Unmodified 
cytosine bases in a CpG dinucleotides can be directly methylated through the actions of the DNA 
methyltransferase enzymes. Demethylation is thought to be both passive (during cell division; dashed 
arrow) as well as active (through a series of enzymatic reactions). TET proteins can oxidize 5mC-
modified bases into 5hmC and then onto 5fC and 5caC derivatives. The oxidized 5fC and 5caC bases 
are thought to provide suitable substrates for rapid demethylation to nonmodified cytosine via 
TDG-coupled base-excision repair. In contrast with these rapidly turned-over intermediates, 5hmC 
appears to remain stable in certain parts of the genome. 
Black arrows: active methylation; dashed arrows: passive demethylation; red arrow: methylation. 
5caC: 5-carboxylcytosine; 5fC: 5-formylcytosine; 5hmC: 5-hydroxymethylcytosine; 
5mC: 5-methylcytosine.
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paternal pronucleus during mouse preimplanta-
tion and the dilution of these factors through 
replication, similar to that described for 5hmC, 
may also suggest that these factors could be 
involved in a passive demethylation process 
[54,72]. While the involvement of 5hmC in the 
demethylation process appears highly plausible, 
the molecular mechanisms through which this 
occurs have yet to be unequivocally identified. It 
is clear that 5hmC is not solely an intermediate 
in this process (unlike the transient marks of 
5fC and 5caC) and is likely to have additional 
unique biological functions.
One such biological role may be associated 
with marking gene transcription. The con-
version of 5mC to 5hmC affects the binding 
affinity of a number of proteins to DNA. There 
have been reports of reduced affinity of MBD1, 
MBD2, MBD4 and MeCP2 to 5hmC [73,74]. 
These are contrasted with reports of signifi-
cant affinity by MBD3 and MeCP2 to 5hmC-
containing substrates [75,76]. 5hmC binding by 
MeCP2 has been reported in extracts derived 
from ES cells, but not in neuronal tissue, while 
MeCP2 was found to be a 5mC reader in mouse 
ES cells, neuronal progenitor cells and adult 
mouse brain tissue [77]. In this analysis, the pro-
tein–DNA interactions were dynamic with, for 
example, neuronal progenitor cell-specific bind-
ing of Uhrf2 to 5hmC. Wdr76 preferentially 
binds to 5hmC and interacts with HELLS, a 
DNA helicase that has been previously impli-
cated in regulating DNA methylation levels in 
cells [78,79]. While the exact consequences of 
altered protein binding have not been eluci-
dated, it may suggest that 5hmC is an impor-
tant contributor to the control of gene tran-
scription through its ability to differentially 
interact with nuclear factors, in addition to 
DNA methylation reprogramming.
5hmC occurs in CpG dinucleotides with an 
asymmetrical strand bias, with a G-rich prefer-
ence in human ES cells [43]. In human somatic 
neural tissue, 5hmC is enriched in promoters 
and intragenic regions, but is largely absent 
from intergenic regions [80]. Moreover, 5hmC 
within gene bodies appears to be preferentially 
located at exons [34,37,81] and is positively cor-
related with gene-expression levels [80], which 
mirrors findings from work on murine neuronal 
tissue [39]. In addition, further work on both 
human and mouse ES cells has shown genic 
5hmC distribution to be related to gene expres-
sion with high 5hmC levels in the gene bodies 
of high- and intermediate-expressed genes com-
pared with low-expressed genes [39,82]. This may 
suggest that there is a mechanism that allows 
TET enzymes to target genes [41], presumably 
for gene activation, although the causative effect 
on gene regulation is yet to be shown. TET1, 2 
and 3 have now been identified as interaction 
partners for OGT. Chromatin immunoprecip-
itation-sequencing experiments demonstrate 
that OGT binding sites on chromatin are co-
occupied by TET enzymes in mouse ES and 
somatic cells [83–86]. In addition, TET proteins 
and OGT activity can promote binding of the 
SET1/COMPASS H3K4 methyltransferase, 
SETD1A, to chromatin [84]. TET2 knockout 
in mouse bone marrow leads to decreases in 
global N-acetyl glycosylation and H3K4me3, 
notably at several key regulators of hemato-
poiesis. Together, these results suggest a novel 
pathway by which the TET enzymes themselves 
may be required for transcriptional activation in 
the absence of their catalytic function. Figure 3 
illustrates the proposed TET, OGT and SET1 
interactions for gene transcription, with typi-
cal 5mC and 5hmC profiles associated with the 
active gene.
Interestingly, in human ES cells, 5hmC has 
been found to be most abundant at regions of 
low CpG density, and promoters with high CpG 
content (e.g., CpG islands) have almost com-
plete absence of 5hmC [43,82]. Study of human 
ES cells also revealed that 5hmC is located 
at regions with a GC skew, in which Gs are 
enriched over Cs in the 5´ end of the region with 
the converse in the 3´ end [87]. It has previously 
been proposed that GC skew may occur at sites 
of replication termination and recombination 
hotspots [88–90] and, as such, 5hmC may also 
mark these sites [87]. 
A major modifier of both global and locus- 
specif ic 5hmC prof ile is tissue type [41]. 
Interestingly, in both mouse and human tissues, 
the brain, which has a low proliferative rate, 
had the highest level of 5hmC, while blood, 
which undergoes significant proliferation dur-
ing hematopoiesis, had the lowest [41]. This 
same study also confirmed loss of 5hmC from 
cells that have adapted to culture. Together, 
these findings may reinforce the role of 5hmC 
in the passive demethylation process, in which 
the proliferative rate of tissue and cells affects 
5hmC levels. This hypothesis is strengthened by 
the findings of Jin et al. who demonstrated with 
immunohistochemistry the mutual exclusivity 
of Ki67, a marker of proliferation and 5hmC 
in tissue [91]. However, the finding of reduced 
TET expression upon cell culture may suggest 
that this is not solely related to proliferation [41].
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5hmC profiling defines cellular state
Recently, accumulation of 5hmC in the devel-
oping mammalian brain has been shown to 
occur in a partly independent process from 
methylation at CpGs [92]. The development 
of adult 5hmC patterns in the brain have also 
been shown to develop in utero, although the 
5hmC pattern in the fetal frontal cortex is 
unique to the stage of fetal development [92]. 
Furthermore, developmentally downregulated 
genes show enrichment of 5hmC in the fetal 
frontal cortex, but not in adults, supporting the 
correlation of reduced transcription with loss of 
5hmC [76,92]. These findings support the role 
of 5hmC as a marker of cellular state, which 
has been demonstrated systematically using a 
nongenotoxic carcinogen (NGC) liver tumor 
mouse model [93,94]. 
It is known that the epigenome can be 
perturbed in response to a group of chemi-
cals called NGCs. Exposure to the NGC 
phenobarbital (PB) can lead to an increase in 
the incidence of spontaneously and chemically 
induced liver tumors in rodents and significantly 
promotes hepatic tumor incidence in B6C3F1 
mice, as well as increasing the size of the tumors 
themselves [95–99].
PB exposure leads to the expression of genes 
that depend on activation of the constitutive 
active androstane receptor. It was recently sug-
gested that PB activates the constitutive active 
androstane receptor by inhibiting EGF receptor 
signaling [100]. Recent work in our laboratory 
shows that the distribution of 5mC/5hmC is 
highly consistent between untreated individual 
mice of a similar age; yet subtle changes during 
liver maturation in a transcriptionally depen-
dent manner occur [93]. Following exposure to 
PB, there are staged transcriptional responses 
corresponding to dose exposure that strongly 
correlate with promoter-proximal region 
5hmC levels, suggesting that 5hmC may be 
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Figure 3. Proposed model of 5-methylcytosine, 5-hydroxymethylcytosine and TeT distribution associated with gene 
transcription. Activation of gene expression can occur through the active demethylation of regions around the TSS (loss of 5mC 
through a 5hmC intermediate) with elevated promoter and gene body 5hmC levels allowing the binding and elongation of the RNAP-II 
complex, probably in concert with histone modification changes (not shown). Conversion of 5mC into 5hmC (and further derivatives) is 
mediated by the TET proteins (blue). TET proteins have been show to interact with OGT, as well as the HCF1, component of the H3K4 
methyltransferase SET1/COMPASS complex, resulting in altered chromatin environments (OGT, HCF1 and SET1 complex: yellow). TDG 
(not shown) is proposed to complete this promoter-specific demethylation through base-excision repair, while regions lacking TDG lead 
to the accumulation of 5hmC (e.g., gene bodies and enhancers), perhaps by tracking the RNAP II complex in the case of gene bodies. 
Typical 5hmC (purple) and 5mC (red) profiles at an actively transcribing gene are shown above. 
5hmC: 5-hydroxymethylcytosine; 5mC: 5-methylcytosine; TF: Transcription factor; TSS: Transcription start site.
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the mechanism that facilitates transcriptional 
changes [93,94]. Furthermore, reciprocal changes 
for both 5mC and 5hmC in response to PB 
suggest that active demethylation may be tak-
ing place at each set of these loci, via a 5hmC 
intermediate. It is possible that these changes 
in 5mC and 5hmC result from variation in 
cell populations and cellular heterogeneity 
in response to stimuli. However, the dynam-
ics of 5hmC turnover appear to be very rapid, 
implying that these reflect true cell autonomous 
changes in the epigenome. As such, this work 
suggests 5hmC profiling can be used as an 
indicator of cell states during organ matura-
tion and drug-induced responses, and provides 
novel epigenetic signatures for NGC exposure. 
Many regions were seen to change dramatically 
in their 5hmC levels following drug exposure. 
By focusing on the promoter regions of strongly 
induced genes, it was observed that these con-
tained elevated levels of 5hmC-marked DNA, 
as well as increased levels of H3K4me2, a his-
tone modification associated with gene acti-
vation [94]. Conversely, these same promoter 
regions were found to lose 5mC. PB-induced 
genes gained H3K36me3 in the body of the 
gene, while losing the repressive histone mark, 
H3K27me3.
Importantly, this work revealed that repro-
ducible interindividual epigenetic perturbations, 
namely changes to the hydroxymethylome, can 
be observed following 24 h of drug dosing and 
that these changes persist or expand over several 
months as the length of exposure continues [93]. 
This raises the exciting possibility that 5hmC is 
a potential biomarker of exposure to particular 
environmental stimuli or risk factors in dis-
ease development. While 5mC patterns have 
been demonstrated to be changed in response 
to environmental stimuli such as smoking [101], 
5hmC may offer additional benefit as a marker 
of specific exposure. This was demonstrated 
with the PB NGC model, as global 5hmC per-
turbations alone were sufficient to stratify drug-
exposed individuals from the control set, while 
5mC and selective histone modifications alone 
did not always reliably report exposure [93,94]. 
It would be important to confirm whether 
these changes remain present and identifiable 
long after exposure in this model, and whether 
these observations in a mouse model system are 
transferable to human disease.
The measurable and reproducible changes 
in 5hmC in response to a drug could conceiv-
ably be used to monitor epigenetic changes 
in the tissue as an indication of a real-time 
response. Furthermore, the alterations observed 
in response to a previously considered ‘nonepi-
genetic modulator’ such as PB, could suggest 
that these profiles may be used to monitor tra-
ditional therapies, as well as newer treatments 
targeted at epigenetic components. One might 
expect a reversal of the ‘cancer signature’ to 
that of the ‘normal tissue signature’ on success-
ful treatment of a disease in a tissue-specific 
manner. This would be particularly important 
in oncological management, where there is a 
void of sensitive and specific markers of disease 
response, and patients often undergo repeated 
ionizing imaging to assess disease burden.
5hmC patterns in cancer
Cancer-related 5hmC pattern changes and pos-
sible underlying mechanisms are summarized 
in Box 1. Reduction in 5hmC is well reported in 
a number of cancers and cell lines correspond-
ing to prostate, breast, colon, lung, brain, liver, 
kidney and melanoma, compared with the 
associated normal tissue [41,91,102]. This hypo-
hydroxymethylation may be due to the cellu-
lar replication-related loss of 5hmC described 
above, ref lecting the increased proliferative 
Box 1. summary of changes in 5-hydoxymethylcytosine patterns and possible 
underlying mechanisms seen in cancer.
  Cancer-associated hydroxymethylcytosine patterns
  General loss of 5hmC
  Cancer-specific redistribution with enrichment, particularly at oncogenic gene activators
  Possible mechanisms for 5hmC changes in cancer
  Replication-related passive demethylation and loss of hydroxymethylcytosine
  Misexpression or mutation of TET enzymes, which are responsible for the oxidative conversion of 
5mC to 5hmC
  Inhibition of the essential TET cofactor, α-ketoglutarate, through mutation of isocitrate 
dehydrogenase or other Krebs cycle enzymes, such as fumerate hydratase or succinate 
dehydrogenase
5mC: 5-methylcytosine; 5hmC: 5-hydroxymethylcytosine.
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rate of the cancer compared with normal tis-
sue. However, there was no correlation between 
levels of 5hmC and 5mC staining in colorectal 
or prostate tumors [102], suggesting the presence 
of alternative mechanisms to the general global 
hypomethylation reported in cancer [103].
Another possible explanation for altered 
5hmC patterns in cancer is the misexpression of 
TET enzymes, which are responsible for 5hmC 
production. While TET3 has been implicated 
in the 5mC decrease, and simultaneous 5hmC 
increase in the male pronucleus upon zygote for-
mation prior to cell division [104–106], there has 
been no association between TET3 expression 
and cancer reported so far.
Prior to the rediscovery of 5hmC with the 
subsequent appreciation of TET involvement in 
the methylation cycle, TET1 was identified as 
a fusion partner of the mixed-lineage leukemia 
in the ten–eleven chromosomal translocation 
t(10;11)(p12;q23) in rare cases of acute myeloid 
leukemia (AML) [107,108]. Whereas the role of 
TET1 in these AML cases is independent of its 
regulation of 5hmC, subsequent loss of TET1 
and changes in 5hmC have been shown in a 
number of solid tumors. In prostate and breast 
cancer, TET1 has been shown to inhibit cancer 
growth and metastases through tissue inhibitors 
of metalloproteases (TIMPs). Conversely, loss 
of TET1 is associated with the de novo meth-
ylation of TIMP2 and TIMP3 and associated 
gene repression, and correlates with poor sur-
vival rates in breast cancer patients [109]. The 
HMGA2-TET1-HOXA9 pathway is coordi-
nately regulated in breast cancer and has been 
reported to encompass a prognostic signature 
for patient survival [110]. Expression of TET1 
and HOXA9 suppresses breast tumor growth 
and metastasis in mouse xenografts. Others have 
demonstrated that loss of 5hmC was associated 
with downregulation of TET1 in hepatocellular 
carcinoma and this was associated with poorer 
overall survival [111]. Clearly, these studies sug-
gest that the loss of TET1 may have an impor-
tant role in the development of an aggressive 
phenotype in cancer.
As well as the alterations of TET1 in cancers, 
TET2 has been implicated in melanoma pro-
gression. Global loss of 5hmC was demonstrated 
in malignant melanoma and this correlated with 
loss of TET expression, particularly TET2 [112]. 
Furthermore, these global changes in 5hmC 
were associated with Breslow score, mitotic rate, 
pathological tumor stage and tumor ulceration, 
all currently used prognostic indicators in malig-
nant melanoma. Loss of 5hmC in melanoma 
patients was also correlated with poorer survival 
on Kaplan–Meier survival analysis [112].
A study in pancreatic cancer has shown that 
there is also a cancer-specific redistribution of 
5hmC, with enrichment in particular oncogenic 
gene activators [113]. The highly tissue-specific 
and dynamic patterns observed for 5hmC distri-
bution could be vital in defining the tissue of ori-
gin of a metastatic cancer, which in turn may aid 
the overall diagnosis and subsequent treatment 
regime [8]. These findings, combined with the 
cell- and tissue-specific distribution of 5hmC, 
suggest a possible prognostic role for 5hmC in 
cancer, although multivariate analysis has not 
been performed to confirm whether 5hmC could 
be independently significant. Furthermore, over-
expression of TET2 in melanoma cells resulted 
in subsequent partial re-establishment of 5hmC 
profiles with inhibition of invasion on cell cul-
ture-based invasion assays and tumor growth 
in vitro using xenograft models [112]. This sug-
gests possible success with therapeutic manipu-
lation of TET2, but also provides support for 
5hmC as a marker of response to treatment.
Despite these changes in TET expression in 
cancer, TET has not been seen to be frequently 
mutated in the large-scale sequencing stud-
ies of solid malignancies [114–117]. This would 
suggest that there are mechanisms, other than 
mutations of the TET genes, which cause these 
changes. Therefore, further work is required 
to understand the mechanisms underpinning 
TET-related 5hmC changes in cancer.
Nonetheless, mutations in TET2 have been 
demonstrated in all subtypes of myeloid malig-
nancies, and TET2 is the most commonly 
mutated gene in myelodysplastic syndrome 
(MDS) [118–123]. These mutations are associated 
with transformation of MDS to AML, as well 
as poorer survival in AML patients [118]. Loss-
of-function mutations in TET2 have also been 
demonstrated as a recurrent event in human 
lymphomas [124]. The breadth of hematological 
malignancy with TET2 mutations may support 
this as an early event in disease development. 
Moreover, unlike the regulatory control of TET 
enzymes on 5hmC in murine ES cells to main-
tain pluripotency [125], it has been shown that 
this mechanism has the reverse function for con-
trol of hematopoietic stem and progenitor cell 
homeostasis. A number of studies using TET2 
mouse models have shown that TET2-null mice 
have increased hematopoietic stem cell num-
bers and that these cells are able to self-renew 
in culture. Furthermore, although these knock-
out mice are viable, they die early as a result 
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of hematological malignancy [124,126–128]. These 
findings, supported by the higher TET2 expres-
sion in differentiated blood cells compared with 
progenitor cells [128], strengthens the argument 
that the correlation of reduced 5hmC and TET2 
mutation in MDS, and other hematological 
malignancies, is due to an early event in hemato-
poiesis, likely to be affecting hematopoietic stem 
and progenitor cells [124]. Importantly, if these 
findings are confirmed then it would indicate 
that disease treatments would need to focus on 
these hematopoietic stem cells.
The third possible contributing mechanism 
for the general loss of 5hmC in cancer is through 
inhibition of TET cofactors. As previously 
described, TET enzymes are 2OG-dependant, 
which is produced through catalytic oxidative 
carboxylation of isocitrate by isocitrate dehy-
drogenases (IDHs) in the Krebs cycle [129,130]. 
There are two homologs of this enzyme, IDH1 
and IDH2, which catalyze the same reaction. 
Gain-of-function mutations of both IDH1 
and IDH2 have been identified in cancer cells. 
These mutations produce the R-enantiomer of 
the oncometabolite 2-hydroxyglutarate (2-HG) 
[131,132]. Both the R- and S-enantiomers of 2-HG 
are structurally similar to 2OG and can antag-
onize the 2OG-dependant reaction [130,133,134], 
thus inhibiting TET-mediated 5mC to 5hmC 
conversion. Significant downregulation of IDH2 
in melanomas compared with benign nevi has 
been shown [112]. Furthermore, overexpression 
of IDH2 in the BRAFV600E zebrafish melanoma 
models significantly increased 5hmC levels, 
with improved progression-free survival [112], 
highlights the possible therapeutic benefit of 
targeting this pathway when mutated.
Recently, through transfection of mutant 
IDH1 in a leukemia cell line (TF1), IDH has 
been shown to be oncogenic through the devel-
opment of growth factor independence and 
impaired differentiation [135]. Interestingly, 
knockdown of TET2 recapitulated these find-
ings, suggesting that IDH inhibition of TET may 
be the mechanism of action. However, paradoxi-
cally, while the IDH1 mutant R-enantiomers, but 
not the S-enantiomers, resulted in the hallmark 
leukemic transformations, the S-enantiomers are 
the greater inhibitor of TET2 [135]. This raises the 
possibility that other 2OG-dependant pathways, 
other than inhibition of TETs may be involved. 
Nonetheless, the changes in growth factor depen-
dence and impaired differentiation induced by 
IDH1 mutation were demonstrated to be revers-
ible through pharmacological blockade of 2-HG. 
While we have indicated that there are potential 
problems of studying TET and 5hmC in cell 
culture, and clearly further work is required to 
understand the subsequent mechanism of tumor-
igenesis following IDH mutation, this does raise 
the possibility of success for 2-HG-blocking 
compounds as therapeutic agents.
As well as the association of IDH dys-
regulation in melanoma, mutations in IDH1 
and IDH2 have been seen in hematological, 
brain, colonic, prostate and thyroid tumors 
[115,132,136–140]. Interestingly, mutations in 
IDH1 have been identified in up to 70% of grade 
2 and 3 gliomas and secondary glioblastomas, 
with most of the remainder harboring mutations 
in IDH2 [138]. These mutations appeared early in 
tumor development and their presence in both 
astrocytoma and oligodendroglioma subtypes 
suggests that these may be early mutations in 
the neural stem cells, a common theme in these 
5hmC/TET/IDH abnormalities. However, 
while IDH mutations in melanoma and cholan-
giocarcinoma studies have correlated with loss 
of 5hmC [112,141], this has not been universally 
demonstrated in brain tumors. IDH1 mutation 
has, however, been linked with a distinct pattern 
of CpG promoter hypermethylation [142], which 
could be interpreted as being a result of a failure 
in the conversion of 5mC to 5hmC through TET 
inhibition. In addition, some brain tumors have 
been shown to have prognostically lower 5hmC 
levels than normal brain tissue. Despite this, 
there has been no correlation with IDH muta-
tions and 5hmC levels in these cancers to date 
[91,143–145]. It therefore raises the possibility that 
IDH mutations may drive oncogenesis through 
alternative pathways to 5hmC. There are a 
number of other 2OG-dependant pathways, 
including the hypoxia-inducible factor propyl-
hydroxylase [146] and JMJC domain-containing 
histone demethylases [147], which could be tar-
geted to promote oncogenesis. Furthermore, 
mutations in succinate dehydrogenase and 
fumarate hydratase identified in a number of 
human cancers including pheochromocytoma, 
paraganglioma and papillary renal cell carci-
noma, result in the accumulation of succinate 
and fumerate, respectively [148–151]. These also 
inhibit 2OG-dependant deoxygenases, and it is 
only recently that the potential impact on TET 
activity has been appreciated with alterations of 
genome-wide DNA methylation being identified 
[152,153]. The complete extent of these changes 
has not been investigated, neither has the role 
of 5hmC. These findings emphasize the likely 
importance of interactions between the Krebs 
cycle, epigenomic regulation and cancer.
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Future perspective & clinical 
applicability
Four years following the rediscovery of 5hmC, 
there has been significant reassessment and prog-
ress in our knowledge of methylation, hydroxy-
methylation and associated changes in disease 
states such as cancer. While the interactions of 
these are complex, and likely tissue-specific, 
there is clear potential for clinical translation of 
some of these findings following more in-depth 
study. These proposed potential strategies for 
the use of 5hmC as a biomarker could help us to 
achieve personalized medicine in which we can 
stratify high-risk patients, prognosticate risk of 
recurrence, predict sensitivity to treatment and 
monitor therapeutic response (Figure 4). These 
possible applications will only be realized if there 
is further large-scale study of 5hmC profiling in 
cancer at diagnosis and sequentially throughout 
therapeutic intervention to define subtype-specific 
patterns of 5hmC, thus allowing us to interpret 
the heterogenous outcomes of patients with the 
same diseases. These studies would also have to 
define and evade epigenetic heterogeneity, which 
we know is a significant problem at a genetic level 
[154]. Furthermore, while predictive and prognos-
tic markers are easily applicable to tumor samples 
at the time of extirpative surgery or diagnostic 
biopsy, the translation of 5hmC as a marker of 
therapeutic response is more complex. Currently, 
sequential tumor sampling through therapeutic 
intervention is not routine. This is for two reasons. 
First, as there are no reliable markers of response, 
there is no benefit to subjecting the patient 
to potentially harmful intervention. Second, 
repeated biopsy may be poorly tolerated by these 
patients. As such, the use of tissue 5hmC profiles 
as a dynamic measure of response will only be 
adopted if significant benefit to the patient can be 
demonstrated, non- (or minimally) invasive mea-
surements can be identified or biopsy techniques 
can be made more tolerable.
Despite this, there is definite potential to add 
to the growing perception that NGS studies can 
make significant contributions to personalized 
medicine. There is certainly mounting evidence 
that 5hmC is involved in DNA methylation 
reprogramming, however, the exact mechanism 
by which this occurs still needs to be confirmed. 
It would also appear that 5hmC has a discrete role 
aside from a demethylation intermediate, as the 
mark persists at select loci at detectable (albeit low) 
levels, while the downstream 5fC and 5caC inter-
mediates are rapidly turned over by base-excision 
repair [30]. It would also appear that there are sig-
nificant correlations between 5hmC profiles and 
gene expression. However, the identification of 
the mechanisms in which this happens need to be 
explored. Irrespective of the mechanism, the tis-
sue- and sample-specific profiles of 5hmC provide 
a unique opportunity for monitoring cell state, 
which may be highly applicable to archived mate-
rial and therapeutic screens. However, although 
there has been progress in profiling 5mC from 
low-quantity and highly fragmented DNA as a 
result of formalin fixation and paraffin-embedded 
tissue [155], there has yet to be any study of 5hmC 
profiles in archival tissue or study of the effect of 
such tissue storage on 5hmC patterns, and this 
is clearly needed. This is especially important 
Figure 4. Potential model of 5-hydroxymethylcytosine biomarker use in the diagnosis and 
management of cancer. (A) Cohort exposed to risk factor for disease. (B) Red population have 
5-hydroxymethylcytosine (5hmC) signature suggestive of sensitivity to this risk factor (black lollipops: 
5-methylcytosine-marked CpGs; purple lollipops: 5hmC marked; white lollipops: unmarked CpGs). 
These patients can undergo close surveillance to allow early detection or pre-emptive treatment, if 
available. Blue patients can be reassured of low risk. (C) Patients develop cancer and can be stratified 
into treatment-sensitive or treatment-resistant groups to allow personalized therapy. (d) Response to 
treatment can be followed. (e) Return to ‘normal’ 5hmC tissue signature on cure.
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executive summary
Discovery & technology
  Standard bisulphite conversion and methylation-specific enzymatic digestion for the elucidation of methylation status cannot differentiate 
between 5-methylcytosine (5mC) and 5-hydroxymethylation (5hmC).
  Antibody-mediated 5hmC-enrichment techniques, glucosylation and purification, or selective restriction enzyme digestion can allow effective 
differential quantification of 5mC and 5hmC.
Function & distribution
  5hmC is involved in DNA methylation reprogramming. However, the exact mechanism, whether passive or active, still needs to be confirmed.
  5hmC is likely to have a distinct role in marking and contributing to control of gene transcription.
Hydroxymethylcytosine profiling defines cellular state
  Global 5hmC levels are tissue-specific. 5hmC profiles are highly conserved in the livers of age-matched mice and are 
transcription-dependant.
  In the nongenotoxic carcinogen mouse model, global 5hmC perturbations alone were sufficient to stratify drug-exposed individuals from the 
control set, while 5mC and selective histone modifications did not always report exposure.
Hydroxymethylcytosine patterns in cancer
  General loss and cancer-specific redistribution of 5hmC has been shown. This may be through replication-dependant demethylation, TET 
inhibition or mutation, or metabolic manipulation by alteration of Krebs cycle enzymes.
Clinical applicability
  Tissue- and cell-specific 5hmC profiles provide a unique opportunity to monitor cellular state and show potential for translation to the clinic 
as diagnostic, prognostic or predictive biomarkers.
  Understanding the role of 5hmC, TETs and isocitrate by isocitrate dehydrogenase in carcinogenesis may provide novel therapeutic 
opportunities.
if fixation methods result in general oxidative 
damage to DNA. If possible, reliable profiling of 
archival tissue would provide a vast resource of 
well-annotated clinical samples to aid biomarker 
discovery.
The roles of TET enzymes and IDH obviously 
stretch beyond regulation of methylation and 
hydroxymethylation and teasing out the interac-
tions will be interesting. In parallel to answer-
ing these mechanistic questions, such knowledge 
would allow the development of epigenetic drugs, 
which could reinstate normal 5hmC patterns, 
either globally or in a locus-specific manner. The 
substantial progress thus far gives promise of 
many exciting developments in this field over the 
coming years. Ultimately, the analysis of global 
5hmC patterns, when combined with other epi-
genetic modifications and transcriptional infor-
mation, will lead to a more refined understanding 
of tumor formation and stratification of specific 
cancer subtypes.
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